# Bioequivalence Study of Ivermectin From Revemact 6 mg Tablets (Man. by EVA Pharma for Horus for Pharmaceutical Industries, Egypt) and Stromectol 2*3 mg Tablets (Merck Sharp & Dohme B.V., Haarlem, The Netherlands)

> **NCT04854460** · PHASE1 · COMPLETED · sponsor: **Genuine Research Center, Egypt** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Revemact
- **DRUG:** Stromectol (first dose)
- **DRUG:** Stromectol (second dose)

## Key facts

- **NCT ID:** NCT04854460
- **Lead sponsor:** Genuine Research Center, Egypt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-28
- **Primary completion:** 2021-02-25
- **Final completion:** 2021-03-22
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04854460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04854460, "Bioequivalence Study of Ivermectin From Revemact 6 mg Tablets (Man. by EVA Pharma for Horus for Pharmaceutical Industries, Egypt) and Stromectol 2*3 mg Tablets (Merck Sharp & Dohme B.V., Haarlem, The Netherlands)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04854460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*